[go: up one dir, main page]

RU2018143284A3 - - Google Patents

Download PDF

Info

Publication number
RU2018143284A3
RU2018143284A3 RU2018143284A RU2018143284A RU2018143284A3 RU 2018143284 A3 RU2018143284 A3 RU 2018143284A3 RU 2018143284 A RU2018143284 A RU 2018143284A RU 2018143284 A RU2018143284 A RU 2018143284A RU 2018143284 A3 RU2018143284 A3 RU 2018143284A3
Authority
RU
Russia
Application number
RU2018143284A
Other versions
RU2738837C2 (ru
RU2018143284A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018143284A publication Critical patent/RU2018143284A/ru
Publication of RU2018143284A3 publication Critical patent/RU2018143284A3/ru
Application granted granted Critical
Publication of RU2738837C2 publication Critical patent/RU2738837C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
RU2018143284A 2016-05-07 2017-05-05 Некоторые ингибиторы протеинкиназы RU2738837C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662333165P 2016-05-07 2016-05-07
US62/333,165 2016-05-07
PCT/CN2017/083162 WO2017193872A1 (en) 2016-05-07 2017-05-05 Certain protein kinase inhibitors

Publications (3)

Publication Number Publication Date
RU2018143284A RU2018143284A (ru) 2020-06-08
RU2018143284A3 true RU2018143284A3 (ru) 2020-07-31
RU2738837C2 RU2738837C2 (ru) 2020-12-17

Family

ID=60266275

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018143284A RU2738837C2 (ru) 2016-05-07 2017-05-05 Некоторые ингибиторы протеинкиназы

Country Status (14)

Country Link
US (1) US10835535B2 (ru)
EP (1) EP3452484B1 (ru)
JP (1) JP6927548B2 (ru)
KR (1) KR102374033B1 (ru)
CN (1) CN109153686B (ru)
AU (1) AU2017262155B2 (ru)
CA (1) CA3023460A1 (ru)
DK (1) DK3452484T3 (ru)
ES (1) ES2954148T3 (ru)
MX (1) MX387648B (ru)
RU (1) RU2738837C2 (ru)
TW (1) TWI752026B (ru)
WO (1) WO2017193872A1 (ru)
ZA (1) ZA201808238B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020008559A (es) 2018-02-15 2021-01-08 Nuvation Bio Inc Compuestos heterocíclicos como inhibidores de la quinasa.
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
CN116836177A (zh) * 2022-09-28 2023-10-03 锦州奥鸿药业有限责任公司 一种蛋白激酶抑制剂的枸橼酸盐、其晶型、制备方法和用途
WO2025085360A1 (en) 2023-10-16 2025-04-24 The Board Of Regents Of The University Of Oklahoma Heteroarotinoids and/or cdk4/6 inhibitors for treating human papillomavirus (hpv)-induced dysplasias, warts, and cancer in hpv-infected subjects

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
ES2214546T3 (es) 1995-09-15 2004-09-16 PHARMACIA & UPJOHN COMPANY N-oxidos de aminoariloxazolidinona.
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
PL1737850T3 (pl) 2004-04-19 2008-02-29 Symed Labs Ltd Nowy sposób wytwarzania linezolidu i związków pokrewnych
US7429661B2 (en) 2004-07-20 2008-09-30 Symed Labs Limited Intermediates for linezolid and related compounds
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
ES2524340T3 (es) 2007-04-19 2014-12-05 Concert Pharmaceuticals Inc. Compuestos de morfinilino deuterados
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
DE102007038251A1 (de) 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellverfahren
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
WO2009045476A1 (en) 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
AU2008317375B2 (en) 2007-10-26 2013-02-28 Concert Pharmaceuticals, Inc. Deuterated darunavir
SI2215094T1 (sl) 2007-11-15 2016-05-31 Ym Biosciences Australia Pty Ltd N vsebujoče heterociklične spojine
KR101353857B1 (ko) 2008-08-22 2014-01-21 노파르티스 아게 Cdk 억제제로서 피롤로피리미딘 화합물
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
FR2988722B1 (fr) * 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
DK3149008T3 (en) 2014-05-28 2019-04-01 Shanghai Fochon Pharmaceutical Co Ltd Specific protein kinase inhibitors
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途

Also Published As

Publication number Publication date
US20190209566A1 (en) 2019-07-11
KR20190025545A (ko) 2019-03-11
RU2738837C2 (ru) 2020-12-17
ES2954148T3 (es) 2023-11-20
MX387648B (es) 2025-03-18
CA3023460A1 (en) 2017-11-16
JP6927548B2 (ja) 2021-09-01
EP3452484A1 (en) 2019-03-13
JP2019516790A (ja) 2019-06-20
RU2018143284A (ru) 2020-06-08
US10835535B2 (en) 2020-11-17
TWI752026B (zh) 2022-01-11
EP3452484A4 (en) 2019-10-09
EP3452484B1 (en) 2023-07-05
WO2017193872A1 (en) 2017-11-16
KR102374033B1 (ko) 2022-03-14
AU2017262155B2 (en) 2021-03-11
DK3452484T3 (da) 2023-09-25
MX2018013573A (es) 2019-08-01
ZA201808238B (en) 2022-10-26
AU2017262155A1 (en) 2018-12-06
CN109153686B (zh) 2021-04-30
CN109153686A (zh) 2019-01-04
TW201805290A (zh) 2018-02-16
BR112018072699A2 (pt) 2019-02-19

Similar Documents

Publication Publication Date Title
BR122021017409A2 (ru)
BR112019002665A2 (ru)
BR112019009366A2 (ru)
RU2018143284A3 (ru)
BR112019009203A2 (ru)
BR202016030146U2 (ru)
CN303537604S (ru)
CN303537760S (ru)
CN303535548S (ru)
CN303535879S (ru)
CN303566256S (ru)
CN303536131S (ru)
CN303536207S (ru)
CN303536214S (ru)
CN303536235S (ru)
CN303536441S (ru)
CN303536492S (ru)
CN303536497S (ru)
CN303536515S (ru)
CN303536550S (ru)
CN303536594S (ru)
CN303536629S (ru)
CN303536867S (ru)
CN303537445S (ru)
CN303553127S (ru)

Legal Events

Date Code Title Description
HE4A Change of address of a patent owner

Effective date: 20220202